Gentamicin and fusidic acid in topical treatment of skin diseases – a discussion Discussion
Article Sidebar
Published:
Sep 30, 2018
Keywords:
gentamicin, fusidic acid, antibiotic therapy, local treatment
Main Article Content
Abstract
Currently, numerous topical dermatological treatment modalities are available, including antibiotics. This article provides comprehensive expert discussion, summarizing the most relevant practical aspects of 2 widely acknowledged drugs: gentamicin and fusidic acid.
Article Details
How to Cite
Reszke, R., & Matusiak, Łukasz. (2018). Gentamicin and fusidic acid in topical treatment of skin diseases – a discussion. Medycyna Faktow (J EBM), 11(3(40), 254-259. https://doi.org/10.24292/01.MF.0318.15
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Del Rosso J.Q., Webster G.F., Rosen T. et al.: Status Report from the Scientific Panel on Antibiotic Use in Dermatology of the American Acne and Rosacea Society: Part 1: Antibiotic Prescribing Patterns, Sources of Antibiotic Exposure, Antibiotic Consumption and Emergence of Antibiotic Resistance, Impact of Alterations in Antibiotic Prescribing, and Clinical Sequelae of Antibiotic Use. J. Clin. Aesthet. Dermatol. 2016; 9: 18-24.
2. Godtfredsen W.O., Jahnsen S., Lorck H. et al.: Fusidic acid: a new antibiotic. Nature 1962; 193: 987.
3. Anonymous. Gentamicin. Br. Med. J. 1967; 1: 158.
4. Rigopoulos D., Larios G.: Fusidic acid: a valuable agent for controlling Staphylococcus aureus skin infections. Acta Derm. Venereol. 2008; Suppl. 216: 7-13.
5. Vaara M.: Agents that increase the permeability of the outer membrane. Microbiol. Rev. 1992; 56: 395-411.
6. Gentamicin TZF. Charakterystyka produktu leczniczego.
7. Curbete M.M., Salgado H.R.: A Critical Review of the Properties of Fusidic Acid and Analytical Methods for Its Determination. Crit. Rev. Anal. Chem. 2016; 46: 352-360.
8. Bedicort G.: Charakterystyka produktu leczniczego.
9. Fucibet Lipid. Charakterystyka produktu leczniczego.
10. Fucidin. Charakterystyka Produktu Leczniczego.
11. Long B.H.: Fusidic acid in skin and soft-tissue infections. Acta Derm. Venereol. 2008; Suppl. 216: 14-20.
12. Gip L.: A new topical steroid-antibiotic combination, diprogenta. Curr. Ther. Res. Clin. Exp. 1974; 16: 581-584.
13. Larsen F.S., Simonsen L., Melgaard A. et al.: An efficient new formulation of fusidic acid and betamethasone 17-valerate (fucicort lipid cream) for treatment of clinically infected atopic dermatitis. Acta Derm. Venereol. 2007; 87: 62-68.
14. Koning S., van der Sande R., Verhagen A.P. et al.: Interventions for impetigo. Cochrane Database Syst. Rev. 2012; 1: CD003261.
15. Strategos J.: Fusidic acid-betamethasone combination in infected eczema: an open, randomized comparison with gentamicin-betamethasone combination. Pharmatherapeutica 1986; 4: 601-606.
16. Sánchez-Borges M., Thong B., Blanca M. et al.: Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy. World Allergy Organ J. 2013; 6: 18.
17. Mingeot-Leclercq M.P., Glupczynski Y., Tulkens P.M.: Aminoglycosides: activity and resistance. Antimicrob. Agents Chemother. 1999; 43: 727-737.
18. Castanheira M., Watters A.A., Bell J.M. et al.: Fusidic acid resistance rates and prevalence of resistance mechanisms among Staphylococcus spp. isolated in North America and Australia, 2007-2008. Antimicrob. Agents Chemother. 2010; 54: 3614-3617.
19. Baek Y.S., Jeon J., Ahn J.W. et al.: Antimicrobial resistance of Staphylococcus aureus isolated from skin infections and its implications in various clinical conditions in Korea. Int. J. Dermatol. 2016; 55: e191-e197.
2. Godtfredsen W.O., Jahnsen S., Lorck H. et al.: Fusidic acid: a new antibiotic. Nature 1962; 193: 987.
3. Anonymous. Gentamicin. Br. Med. J. 1967; 1: 158.
4. Rigopoulos D., Larios G.: Fusidic acid: a valuable agent for controlling Staphylococcus aureus skin infections. Acta Derm. Venereol. 2008; Suppl. 216: 7-13.
5. Vaara M.: Agents that increase the permeability of the outer membrane. Microbiol. Rev. 1992; 56: 395-411.
6. Gentamicin TZF. Charakterystyka produktu leczniczego.
7. Curbete M.M., Salgado H.R.: A Critical Review of the Properties of Fusidic Acid and Analytical Methods for Its Determination. Crit. Rev. Anal. Chem. 2016; 46: 352-360.
8. Bedicort G.: Charakterystyka produktu leczniczego.
9. Fucibet Lipid. Charakterystyka produktu leczniczego.
10. Fucidin. Charakterystyka Produktu Leczniczego.
11. Long B.H.: Fusidic acid in skin and soft-tissue infections. Acta Derm. Venereol. 2008; Suppl. 216: 14-20.
12. Gip L.: A new topical steroid-antibiotic combination, diprogenta. Curr. Ther. Res. Clin. Exp. 1974; 16: 581-584.
13. Larsen F.S., Simonsen L., Melgaard A. et al.: An efficient new formulation of fusidic acid and betamethasone 17-valerate (fucicort lipid cream) for treatment of clinically infected atopic dermatitis. Acta Derm. Venereol. 2007; 87: 62-68.
14. Koning S., van der Sande R., Verhagen A.P. et al.: Interventions for impetigo. Cochrane Database Syst. Rev. 2012; 1: CD003261.
15. Strategos J.: Fusidic acid-betamethasone combination in infected eczema: an open, randomized comparison with gentamicin-betamethasone combination. Pharmatherapeutica 1986; 4: 601-606.
16. Sánchez-Borges M., Thong B., Blanca M. et al.: Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy. World Allergy Organ J. 2013; 6: 18.
17. Mingeot-Leclercq M.P., Glupczynski Y., Tulkens P.M.: Aminoglycosides: activity and resistance. Antimicrob. Agents Chemother. 1999; 43: 727-737.
18. Castanheira M., Watters A.A., Bell J.M. et al.: Fusidic acid resistance rates and prevalence of resistance mechanisms among Staphylococcus spp. isolated in North America and Australia, 2007-2008. Antimicrob. Agents Chemother. 2010; 54: 3614-3617.
19. Baek Y.S., Jeon J., Ahn J.W. et al.: Antimicrobial resistance of Staphylococcus aureus isolated from skin infections and its implications in various clinical conditions in Korea. Int. J. Dermatol. 2016; 55: e191-e197.